Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Type:
Application
Filed:
August 23, 2023
Publication date:
March 21, 2024
Applicant:
Genomic Health, Inc.
Inventors:
Wayne Cowens, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre Baker, Michael C. Kiefer, Tara MADDALA, Frederick L. Baehner
Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
Type:
Application
Filed:
April 4, 2023
Publication date:
November 23, 2023
Applicant:
Genomic Health, Inc.
Inventors:
Margarita LOPATIN, Athanasios TSIATIS, Christopher N. SILK, David P. MILLER, Michael R. CRAGER, Phillip FEBBO, Dejan KNEZEVIC
Abstract: Some embodiments presented in this disclosure concern an Automated Tissue Dissection (ATD) System. An ATD system is a one stop, and potentially low-cost, system to perform dissections on a substrate from pathologist digital mark or pen mark on the substrate using non-contact and/or mechanical method to extract a Formalin-Fixed Paraffin-Embedded (FFPE) tissue sample with: (a) only the ROI or ROIs as area to be saved; and (b) remove or decompose nucleic acid content in the region of no interest (RONI) and collect all tissue sample from a standard microscope substrate into a specific container.
Type:
Grant
Filed:
June 21, 2019
Date of Patent:
November 7, 2023
Assignee:
Genomic Health, Inc.
Inventors:
Hubert Yeung, Amy Lee Hsieh Yuan, Chun Wai Lee, Gabriel Jesus Samuel Perlas Moraleda, Jonathan M. Cassel
Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Type:
Grant
Filed:
November 19, 2020
Date of Patent:
October 3, 2023
Assignee:
Genomic Health, Inc.
Inventors:
Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
May 16, 2023
Assignee:
Genomic Health, Inc.
Inventors:
Margarita Lopatin, Athanasios Tsiatis, Christopher N. Silk, David P. Miller, Michael Crager, Phillip Febbo, Dejan Knezevic
Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
Type:
Grant
Filed:
November 2, 2020
Date of Patent:
January 10, 2023
Assignee:
Genomic Health, Inc.
Inventors:
Steven Shak, George Andrew Watson, Michael R. Crager, Tara Maddala, Margarita Lopatin, Audrey Goddard, Dejan Knezevic, Christer Svedman
Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Type:
Application
Filed:
November 19, 2020
Publication date:
February 17, 2022
Applicant:
Genomic Health, Inc.
Inventors:
Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
Type:
Application
Filed:
November 2, 2020
Publication date:
February 10, 2022
Applicant:
Genomic Health, Inc.
Inventors:
Steven SHAK, George Andrew WATSON, Michael R. CRAGER, Tara MADDALA, Margarita LOPATIN, Audrey GODDARD, Dejan KNEZEVIC, Christer SVEDMAN
Abstract: The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation.
Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Type:
Application
Filed:
November 19, 2020
Publication date:
June 3, 2021
Applicant:
Genomic Health, Inc.
Inventors:
Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.
Type:
Application
Filed:
November 2, 2020
Publication date:
May 20, 2021
Applicant:
Genomic Health, Inc.
Inventors:
Steven SHAK, George Andrew WATSON, Michael R. CRAGER, Tara MADDALA, Margarita LOPATIN, Audrey GODDARD, Dejan KNEZEVIC, Christer SVEDMAN
Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
Type:
Grant
Filed:
May 2, 2017
Date of Patent:
May 18, 2021
Assignee:
Genomic Health, Inc.
Inventors:
Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
Abstract: The present invention provides methods to determine the prognosis and appropriate treatment for patients diagnosed with cancer, based on the expression levels of one or more biomarkers. More particularly, the invention relates to the identification of genes, or sets of genes, able to distinguish breast cancer patients with a good clinical prognosis from those with a bad clinical prognosis. The invention further provides methods for providing a personalized genomics report for a cancer patient. The inventions also relates to computer systems and software for data analysis using the prognostic and statistical methods disclosed herein.
Type:
Application
Filed:
September 11, 2020
Publication date:
March 4, 2021
Applicant:
GENOMIC HEALTH, INC.
Inventors:
Joffre B. BAKER, Maureen T. CRONIN, Francois COLLIN, Mei-Lan LIU
Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
Type:
Grant
Filed:
December 5, 2016
Date of Patent:
January 12, 2021
Assignee:
Genomic Health, Inc.
Inventors:
Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
Type:
Application
Filed:
March 3, 2020
Publication date:
September 24, 2020
Applicant:
Genomic Health, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
Abstract: The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient. The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.
Type:
Application
Filed:
February 7, 2020
Publication date:
August 20, 2020
Applicant:
GENOMIC HEALTH, INC.
Inventors:
Joffre B. BAKER, Dominick SINICROPI, Robert J. PELHAM, Michael R. CRAGER, Francois COLLIN, James C. STEPHANS, Mei-Lan LIU, John D. MORLAN, Kunbin QU
Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
Type:
Application
Filed:
February 25, 2020
Publication date:
August 13, 2020
Applicant:
GENOMIC HEALTH, INC.
Inventors:
Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
Abstract: The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.
Type:
Application
Filed:
May 17, 2018
Publication date:
May 28, 2020
Applicant:
Genomic Health, Inc.
Inventors:
Margarita LOPATIN, Athanasios TSIATIS, Christopher N. SILK, David P. Miller, Michael CRAGER, Phillip FEBBO, Dejan KNEZEVIC
Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
April 14, 2020
Assignee:
Genomic Health, Inc.
Inventors:
Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak